NEOSPHERE trial

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:Clinical_Trials
gptkbp:aims_to_improve treatment efficacy
safety profile
gptkbp:associated_with HER2-targeted therapy
gptkbp:clinical_trial neoadjuvant trials
NCT01042379
other HER2 studies
gptkbp:collaborator academic institutions
gptkbp:collection clinical assessments
patient-reported outcomes
biomarker analysis
gptkbp:completed gptkb:2013
gptkbp:conducted clinical researchers
gptkbp:criteria pregnancy
previous cancer treatment
stage II or III breast cancer
HER2-positive status
gptkbp:events ongoing research
quality of life assessments
long-term outcomes analysis
gptkbp:finale_date efficacy of treatment
safety of treatment
gptkbp:focuses_on gptkb:HER2-positive_breast_cancer
gptkbp:funding government grants
private funding
https://www.w3.org/2000/01/rdf-schema#label NEOSPHERE trial
gptkbp:investigates neoadjuvant therapy
gptkbp:involves gptkb:pertuzumab
gptkb:trastuzumab
chemotherapy
gptkbp:is_studied_in randomized controlled trial
gptkbp:is_tested_for Phase II
gptkbp:location multiple sites
gptkbp:notable_work improved p CR rates
potential for new treatment protocols
tolerable side effects
gptkbp:outcome clinical practice
gptkbp:participants overall survival
patients with breast cancer
disease-free survival
pathological complete response
gptkbp:provides_guidance_on breast cancer treatment guidelines
HER2 therapy recommendations
gptkbp:recruitment completed
gptkbp:research_areas oncology
breast cancer research
clinical oncology
gptkbp:result gptkb:2015
medical journals
gptkbp:sponsored_by pharmaceutical companies
gptkbp:started_in gptkb:2010
gptkbp:bfsParent gptkb:pertuzumab
gptkb:Pertuzumab
gptkbp:bfsLayer 6